Intellectual Property India Publishes Patent Application for Design, Development, And Optimization Of A Lyophilized Liposomal Amphotericin B Formulation Using Box–behnken Experimental Design Incorporating Hspc, Cholesterol, And Trehalose For Enhanced Entrapment Efficiency, Controlled Particle Size Distribution, Reduced Hemolytic Toxicity, And Improved Systemic Antifungal Performance

MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202611055904 A) filed by Prevesh Kumar; Rakesh Arya; Somesh Thapliyal; Chirayu Sharma; Ragini Bose; Kunal Narayanbhai Patel; Sumana Roy; Sanchari Bhattacharya; Priyanka Ray; Keyur Shankarlal Patel; Switi Buch; and Pinki Biswas on May 01, 2026, for Design, Development, And Optimization Of A Lyophilized Liposomal Amphotericin B Formulation Using Box–behnken Experimental Design Incorporating Hspc, Cholesterol, And Trehalose For Enhanced Entrapment Efficiency, Controlled Particle Size Distribution, Reduced Hemolytic Toxicity, And Improved Systemic Antifungal Performance.

Inventors include Prevesh Kumar; Rakesh Arya; Somesh Thapliyal; Chirayu Sharma; Ragini Bose; Kunal Narayanbhai Patel; Sumana Roy; Sanchari Bhattacharya; Priyanka Ray; Keyur Shankarlal Patel; Switi Buch; and Pinki Biswas.

The application for the patent was published on July 17, 2026, under issue no. 29/2026.

Abstract: The present invention relates to a lyophilized liposomal Amphotericin B formulation optimized using Box–Behnken experimental design. The formulation comprises Amphotericin B, hydrogenated soy phosphatidylcholine, cholesterol, and trehalose. HSPC forms a rigid liposomal bilayer for incorporation of Amphotericin B, cholesterol stabilizes the bilayer and reduces drug leakage, and trehalose protects the vesicles during freezing, drying, storage, and reconstitution. The formulation is prepared by lipid film formation, hydration, vesicle size reduction, trehalose addition, and lyophilization. Box–Behnken experimental design is used to optimize HSPC, cholesterol, and trehalose concentrations with respect to particle size, polydispersity index, entrapment efficiency, reconstitution time, leakage, hemolytic toxicity, and antifungal performance. The optimized formulation provides high Amphotericin B entrapment efficiency, controlled particle size distribution, reduced hemolytic toxicity, improved storage stability, rapid reconstitution, and improved systemic antifungal performance for the treatment of systemic fungal infections. (Accompanied Figure No. 1)

Disclaimer: Curated by HT Syndication.